Xcout Intel
Nostopharma, LLC
Nostopharma is a women-owned biopharmaceutical company that develops novel precision delivery therapies and molecular interventions for patients with bone and connective tissue disorders. The company focuses on repurposing existing Hedgehog pathway inhibitors to prevent the onset of symptoms, slow disease progression, and treat conditions such as heterotopic ossification.
Subscribe to see Nostopharma, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nostopharma, LLC at a glance
Nostopharma, LLC is a biotechnology company headquartered in United States. It has raised at least $500,000 across the 2 funding rounds on record. Its most recent funding round raised $250,000 in September 2024. Xcout tracks 3 named people at Nostopharma, LLC, including Ekaterina Vert-Wong (Chief Executive Officer).
Nostopharma, LLC leadership
- Ekaterina Vert-WongChief Executive Officer
- Ekaterina Vert-WongExecutive Officer
- Jelena Gvozdenovic-JeremicExecutive Officer
Nostopharma, LLC funding rounds
At least $500,000 raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $250,000 | — | |
| SEC Form D filing | $250,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Nostopharma, LLC competitors
A few of Nostopharma, LLC's closest competitors — see the full list of competitors and alternatives →
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Get Nostopharma, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Nostopharma, LLC in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access